admin

Por Damian McNamar Un panel de expertos en enfermedades infecciosas advierte contra el uso rutinario de bamlanivimab (Eli Lilly) y señala que el remdesivir (Veklury) puede acortar el curso clínico de COVID-19, que podría ser crítico «a medida que los hospitales se llenen» en los Estados Unidos. El grupo también dijo que los anticuerpos monoclonales […]

 Por Gregory Katz, MD y Harry S. Saag, MD  Parece que tenemos al menos dos vacunas en camino que podrían poner fin a esta pandemia.  Finalmente hay una luz al final del túnel.  No nos malinterprete, los próximos meses parecen que van a ser muy malos, pero las noticias sobre las vacunas Pfizer y Moderna que

Paul E. Sax, MD The latest COVID-19 treatment available under Emergency Use Authorization (EUA) is bamlanivimab, a monoclonal antibody developed by Eli Lilly. For now, its use will be limited to outpatients at high risk of severe illness and/or hospitalization. This EUA is based on the results of the study

Experts from the organization point out that, to date, there is no conclusive evidence that it reduces mortality rates or shortens recovery time. By Amado Herrero. The World Health Organization (WHO) has recommended that doctors not include the antiviral drug remdesivir in the treatment of

Doctors should routinely include the many and varied benefits of viral suppression in their conversations with patients. By José Fley. A US study, whose results have been published in the journal AIDS Patient Care and STDs, has revealed that the message U=U –undetectable equals untransmittable– makes

By Killian Meara The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to long-acting injectable cabotegravir for HIV pre-exposure prophylaxis (PrEP), which was recently announced by ViiV Healthcare. This designation was based on a randomized, multicenter, double-blind, phase 2b/3 clinical trial.

Damian McNamara The final analysis of the randomized phase 3 study of more than 43,000 people yielded 170 confirmed cases of COVID-19, with 162 positive cases in the placebo group versus eight in the BNT162b2 vaccine group. Researchers reported 10 severe cases of COVID-19 in the trial, nine of which

US scientists also point out that the probability of reinfection by coronavirus is very low. MEDICAL NEWSROOM A group of scientists from Wuhan Hospital, in China, and the Institute of Virology at Essen Hospital, in Germany, have published an article on the medical website bioRxiv where they analyze the duration of immune memory

Fever, cough, and shortness of breath should raise concern about a more serious condition; common cold symptoms and loss of smell and taste indicate a lower risk. Thanks to its registry, the Spanish Society of Internal Medicine (SEMI) has categorized COVID-19 patients into four main phenotypic groups, one of which has a poor prognosis and a high risk of ICU admission.

Written by Timothy Huzar. A new study has highlighted the prevalence of gastrointestinal symptoms in people with COVID-19 and what signs abdominal radiologists should look out for. In a new study, researchers synthesized evidence from 36 scientific articles to highlight the prevalence of gastrointestinal symptoms in people with COVID-19. The study,